- Home
- GYRE vs HIFS Comparison
GYRE vs HIFS Comparison
Compare GYRE & HIFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- HIFS
- Stock Information
- Founded
- GYRE 2002
- HIFS 1834
- Country
- GYRE United States
- HIFS United States
- Employees
- GYRE N/A
- HIFS N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- HIFS Major Banks
- Sector
- GYRE Health Care
- HIFS Finance
- Exchange
- GYRE Nasdaq
- HIFS Nasdaq
- Market Cap
- GYRE 755.7M
- HIFS 644.0M
- IPO Year
- GYRE N/A
- HIFS N/A
- Fundamental
- Price
- GYRE $8.19
- HIFS $284.81
- Analyst Decision
- GYRE Strong Buy
- HIFS
- Analyst Count
- GYRE 2
- HIFS 0
- Target Price
- GYRE $17.00
- HIFS N/A
- AVG Volume (30 Days)
- GYRE 60.0K
- HIFS 71.7K
- Earning Date
- GYRE 11-07-2025
- HIFS 10-10-2025
- Dividend Yield
- GYRE N/A
- HIFS 0.89%
- EPS Growth
- GYRE N/A
- HIFS 94.74
- EPS
- GYRE 0.04
- HIFS 20.54
- Revenue
- GYRE $107,265,000.00
- HIFS $90,528,000.00
- Revenue This Year
- GYRE $15.25
- HIFS N/A
- Revenue Next Year
- GYRE $33.14
- HIFS N/A
- P/E Ratio
- GYRE $211.54
- HIFS $13.75
- Revenue Growth
- GYRE 2.13
- HIFS 54.99
- 52 Week Low
- GYRE $6.11
- HIFS $209.71
- 52 Week High
- GYRE $19.00
- HIFS $320.00
- Technical
- Relative Strength Index (RSI)
- GYRE 59.01
- HIFS 49.56
- Support Level
- GYRE $7.12
- HIFS $276.21
- Resistance Level
- GYRE $7.42
- HIFS $292.67
- Average True Range (ATR)
- GYRE 0.34
- HIFS 12.52
- MACD
- GYRE 0.04
- HIFS -1.51
- Stochastic Oscillator
- GYRE 94.82
- HIFS 20.28
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.